Nanotechnology-Driven Therapeutic Innovations in Neurodegenerative Disorders: A Focus on Alzheimer’s and Parkinson’s Disease
Abstract
:1. Introduction
2. Applications of Nanotechnology in Neurological Diseases and Disorders
2.1. Molecular Imaging (MI)
2.1.1. Innovations in Protein Aggregation Imaging for Neurodegenerative Disorders
2.1.2. PET Imaging and Nanoparticles’ Role in Advancing Molecular Imaging in Brain Diseases
2.2. Detection of Biomarkers
2.3. Drug Delivery
3. Nanoparticles in Neurodegenerative Diseases
3.1. Alzheimer’s Disease
3.1.1. Nanoparticle-Based Therapy: Aducanumab
3.1.2. Lacenemab
3.2. Parkinson’s Disease
3.3. Hungtington’s Disease
4. Nanoparticles and Nanomedicine
4.1. Nanopharmaceuticals Currently on the Market and Clinical Trials in Progress
4.2. Challenges of Nanoparticles
5. Future Perspectives
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Kovacs, G.G. Concepts and classification of neurodegenerative diseases. Handb. Clin. Neurol. 2017, 145, 301–307. [Google Scholar] [CrossRef] [PubMed]
- Dugger, B.N.; Dickson, D.W. Pathology of Neurodegenerative Diseases. Cold Spring Harb. Perspect. Biol. 2017, 9, a028035. [Google Scholar] [CrossRef] [PubMed]
- Uchikado, H.; DelleDonne, A.; Ahmed, Z.; Dickson, D.W. Lewy bodies in progressive supranuclear palsy represent an independent disease process. J. Neuropathol. Exp. Neurol. 2006, 65, 387–395. [Google Scholar] [CrossRef] [PubMed]
- Ghasemi, M.; Brown, R.H.J. Genetics of Amyotrophic Lateral Sclerosis. Cold Spring Harb. Perspect. Med. 2018, 8, a024125. [Google Scholar] [CrossRef] [PubMed]
- Jagaran, K.; Singh, M. Nanomedicine for Neurodegenerative Disorders: Focus on Alzheimer’s and Parkinson’s Diseases. Int. J. Mol. Sci. 2021, 22, 9082. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Ding, C.; Wu, Y.; Chen, X.; Chen, Y.; Wu, Z.; Lin, Z.; Kang, D.; Fang, W.; Chen, F. Global, regional, and national burden and attributable risk factors of neurological disorders: The Global Burden of Disease study 1990–2019. Front. Public Health 2022, 10, 952161. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Ghosh, P.; Higgins, D.E. Listeria monocytogenes Infection of the Brain. J. Vis. Exp. 2018, 140, e58723. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Borsche, M.; König, I.R.; Delcambre, S.; Petrucci, S.; Balck, A.; Brüggemann, N.; Zimprich, A.; Wasner, K.; Pereira, S.L.; Avenali, M.; et al. Mitochondrial damage-associated inflammation highlights biomarkers in PRKN/PINK1 parkinsonism. Brain 2020, 143, 3041–3051. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Baccarini, C.I.; Simon, M.W.; Brandon, D.; Christensen, S.; Jordanov, E.; Dhingra, M.S. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Meningococcal-Naïve Children 2–9 Years of Age: A Phase III, Randomized Study. Pediatr. Infect. Dis. J. 2020, 39, 955–960. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Pardridge, W.M. Drug transport across the blood-brain barrier. J. Cereb. Blood Flow. Metab. 2012, 32, 1959–1972. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Ngowi, E.E.; Wang, Y.Z.; Qian, L.; Helmy, Y.A.S.H.; Anyomi, B.; Li, T.; Zheng, M.; Jiang, E.S.; Duan, S.F.; Wei, J.S.; et al. The Application of Nanotechnology for the Diagnosis and Treatment of Brain Diseases and Disorders. Front. Bioeng. Biotechnol. 2021, 9, 629832. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Rabanel, J.M.; Piec, P.A.; Landri, S.; Patten, S.A.; Ramassamy, C. Transport of PEGylated-PLA nanoparticles across a blood brain barrier model, entry into neuronal cells and in vivo brain bioavailability. J. Control Release 2020, 328, 679–695. [Google Scholar] [CrossRef] [PubMed]
- Zielińska, A.; Carreiró, F.; Oliveira, A.M.; Neves, A.; Pires, B.; Venkatesh, D.N.; Durazzo, A.; Lucarini, M.; Eder, P.; Silva, A.M.; et al. Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology. Molecules 2020, 25, 3731. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Rasouli, M.R.; Tabrizian, M. An ultra-rapid acoustic micromixer for synthesis of organic nanoparticles. Lab. Chip. 2019, 19, 3316–3325. [Google Scholar] [CrossRef] [PubMed]
- Matsuno, J.; Kanamaru, T.; Arai, K.; Tanaka, R.; Lee, J.H.; Takahashi, R.; Sakurai, K.; Fujii, S. Synthesis and characterization of nanoemulsion-mediated core crosslinked nanoparticles, and in vivo pharmacokinetics depending on the structural characteristics. J. Control Release 2020, 324, 405–412. [Google Scholar] [CrossRef] [PubMed]
- Zhang, M.; Viennois, E.; Prasad, M.; Zhang, Y.; Wang, L.; Zhang, Z.; Han, M.K.; ** electrochemical analysis of metal nanoparticles. Curr. Opin. Electrochem. 2019, 13, 147–156. [Google Scholar] [CrossRef]
- Liu, Y.; Zhou, H.; Yin, T.; Gong, Y.; Yuan, G.; Chen, L.; Liu, J. Quercetin-modified gold-palladium nanoparticles as a potential autophagy inducerfor the treatment of Alzheimer’s disease. J. Colloid. Interface Sci. 2019, 552, 388–400. [Google Scholar] [CrossRef]
- Kanat, O.; Ertas, H.; Caner, B. Platinum-induced neurotoxicity: A review of possible mechanisms. World, J. Clin. Oncol. 2017, 8, 329–335. [Google Scholar] [CrossRef] [PubMed]
- Chaudhary, S.; Umar, A.; Mehta, S. Selenium nanomaterials: An overview of recent developments in synthesis, properties and potential applications. Prog. Mater. Sci. 2016, 83, 270–329. [Google Scholar] [CrossRef]
- Maiyo, F.; Singh, M. Folate-Targeted mRNA Delivery Using Chitosan Functionalized Selenium Nanoparticles: Potential in Cancer Immunotherapy. Pharmaceuticals 2019, 12, 164. [Google Scholar] [CrossRef]
- Singh, D.; Singh, M. Hepatocellular-Targeted mRNA Delivery using functionalized Selenium Nanoparticles in vitro. Pharmaceutics 2021, 13, 298. [Google Scholar] [CrossRef]
- Moodley, T.; Singh, M. Sterically Stabilized Polymeric Mesoporous Silica Nanoparticles Improve Doxorubicin Efficiency: Tailored Cancer Therapy. Molecules 2020, 25, 742. [Google Scholar] [CrossRef] [PubMed]
- Doadrio, A.L.; Sánchez-Montero, J.M.; Doadrio, J.C.; Salinas, A.J.; Vallet-Regí, M. Mesoporous silica nanoparticles as a new carrier methodology in the controlled release of the active components in a polypill. Eur. J. Pharm. Sci. 2017, 97, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Padayachee, J.; Daniels, A.N.; Balgobind, A.; Ariatti, M.; Singh, M. HER-2/neu and MYC gene silencing in breast cancer: Therapeutic potential and advancement in non-viral nanocarrier systems. Nanomedicine 2020, 15, 1437–1452. [Google Scholar] [CrossRef]
- Nday, C.M.; Halevas, E.; Jackson, G.E.; Salifoglou, A. Quercetin encapsulation in modified silica nanoparticles: Potential use against Cu(II)-induced oxidative stress in neurodegeneration. J. Inorg. Biochem. 2015, 145, 51–64. [Google Scholar] [CrossRef] [PubMed]
- Almaki, J.H.; Nasiri, R.; Idris, A.; Majid, F.A.A.; Salouti, M.; Wong, T.S.; Dabagh, S.; Marvibaigi, M.; Amini, N. Synthesis, characterization and in vitro evaluation of exquisite targeting SPIONs–PEG–HER in HER2+ human breast cancer cells. Nanotechnology 2016, 27, 105601. [Google Scholar] [CrossRef] [PubMed]
- Mngadi, S.; Mokhosi, S.; Singh, M.; Mdlalose, W.B. Chitosan-functionalized Mg0.5Co0.5Fe2O4 magnetic nanoparticles enhance delivery of 5-fluorouracil in vitro. Coatings 2020, 10, 446. [Google Scholar] [CrossRef]
- Ramnandan, D.; Mokhosi, S.; Daniels, A.; Singh, M. Chitosan, Polyethylene glycol and Polyvinyl alcohol modified MgFe2O4 ferrite magnetic nanoparticles in Doxorubicin delivery: A comparative study in vitro. Molecules 2021, 26, 3893. [Google Scholar] [CrossRef]
- Ansari, M.O.; Ahmad, M.F.; Shadab, G.G.H.A.; Siddique, H.R. Superparamagnetic iron oxide nanoparticles based cancer theranostics: A double edge sword to fight against cancer. J. Drug Deliv. Sci. Technol. 2018, 45, 177–183. [Google Scholar] [CrossRef]
- Sanginario, A.; Miccoli, B.; Demarchi, D. Carbon Nanotubes as an Effective Opportunity for Cancer Diagnosis and Treatment. Biosensors 2017, 7, 9. [Google Scholar] [CrossRef] [PubMed]
- Mbatha, L.S.; Maiyo, F.; Daniels, A.; Singh, M. Dendrimer-coated Gold Nanoparticles for Efficient Folate-Targeted mRNA Delivery in vitro. Pharmaceutics 2021, 13, 900. [Google Scholar] [CrossRef] [PubMed]
- Mbatha, L.S.; Maiyo, F.C.; Singh, M. Dendrimer Functionalized Folate-Targeted Gold Nanoparticles for Luciferase Gene Silencing in vitro: A Proof of Principle Study. Acta Pharm. 2019, 69, 49–61. [Google Scholar] [CrossRef] [PubMed]
- Akinyelu, A.; Oladimeji, O.; Singh, M. Lactobionic Acid-Chitosan Functionalized Gold Coated Poly (lactide-co-glycolide) Nanoparticles for Hepatocyte Targeted Gene Delivery. Adv. Nat. Sci. Nanosci. Nanotechnol. 2020, 11, 045017. [Google Scholar] [CrossRef]
- Sánchez-López, E.; Ettcheto, M.; Egea, M.A.; Espina, M.; Cano, A.; Calpena, A.C.; Camins, A.; Carmona, N.; Silva, A.M.; Souto, E.B.; et al. Memantine loaded PLGA PEGylated nanoparticles for Alzheimer’s disease: In vitro and in vivo characterization. J. Nanobiotechnol. 2018, 16, 32. [Google Scholar] [CrossRef] [PubMed]
- Li, W.; Zhou, Y.; Zhao, N.; Hao, B.; Wang, X.; Kong, P. Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes. Environ. Toxicol. Pharmacol. 2012, 34, 272–279. [Google Scholar] [CrossRef] [PubMed]
- Tong-un, T.; Wannanon, P.; Wattanathorn, J.; Phachonpai, W. Cognitive-enhancing and antioxidant activities of quercetin liposomes in animal model of Alzheimer’s disease. J. Biol. Sci. 2010, 10, 84–91. [Google Scholar] [CrossRef]
- Kassem, L.M.; Ibrahim, N.A.; Farhana, S.A. Nanoparticle Therapy Is a Promising Approach in the Management and Prevention of Many Diseases: Does It Help in Curing Alzheimer Disease? J. Nanotechnol. 2020, 2020, 8147080. [Google Scholar] [CrossRef]
- Ventola, C.L. Progress in nanomedicine: Approved and investigational nanodrugs. Pharm. Ther. 2017, 42, 742–755. [Google Scholar]
- D’Mello, S.R.; Cruz, C.N.; Chen, M.L.; Kapoor, M.; Lee, S.L.; Tyner, K.M. The evolving landscape of drug products containing nanomaterials in the United States. Nat. Nanotechnol. 2017, 12, 523–529. [Google Scholar] [CrossRef] [PubMed]
- Maier-Hauff, K.; Ulrich, F.; Nestler, D.; Niehoff, H.; Wust, P.; Thiesen, B.; Orawa, H.; Budach, V.; Jordan, A. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J. Neurooncol. 2011, 103, 317–324. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Eckes, J.; Schmah, O.; Siebers, J.W.; Groh, U.; Zschiedrich, S.; Rautenberg, B.; Hasenburg, A.; Jansen, M.; Hug, M.J.; Winkler, K.; et al. Kinetic targeting of pegylated liposomal doxorubicin: A new approach to reduce toxicity during chemotherapy (CARL-trial). BMC Cancer 2011, 11, 337. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Young, J.S.; Bernal, G.; Polster, S.P.; Nunez, L.; Larsen, G.F.; Mansour, N.; Podell, M.; Yamini, B. Convection-Enhanced Delivery of Polymeric Nanoparticles Encapsulating Chemotherapy in Canines with Spontaneous Supratentorial Tumors. World Neurosurg. 2018, 117, e698–e704. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Abdolahi, M.; Tafakhori, A.; Togha, M.; Okhovat, A.A.; Siassi, F.; Eshraghian, M.R.; Sedighiyan, M.; Djalali, M.; Mohammadzadeh Honarvar, N.; Djalali, M. The synergistic effects of ω-3 fatty acids and nano-curcumin supplementation on tumor necrosis factor (TNF)-α gene expression and serum level in migraine patients. Immunogenetics 2017, 69, 371–378. [Google Scholar] [CrossRef] [PubMed]
- Abdolahi, M.; Jafarieh, A.; Sarraf, P.; Sedighiyan, M.; Yousefi, A.; Tafakhori, A.; Abdollahi, H.; Salehinia, F.; Djalali, M. The Neuromodulatory Effects of ω-3 Fatty Acids and Nano-Curcumin on the COX-2/ iNOS Network in Migraines: A Clinical Trial Study from Gene Expression to Clinical Symptoms. Endocr. Metab. Immune Disord. Drug Targets 2019, 19, 874–884. [Google Scholar] [CrossRef] [PubMed]
- Soveyd, N.; Abdolahi, M.; Djalali, M.; Hatami, M.; Tafakhori, A.; Sarraf, P.; Honarvar, N.M. The Combined Effects of ω -3 Fatty Acids and Nano-Curcumin Supplementation on Intercellular Adhesion Molecule-1 (ICAM-1) Gene Expression and Serum Levels in Migraine Patients. CNS Neurol. Disord. Drug Targets 2018, 16, 1120–1126. [Google Scholar] [CrossRef] [PubMed]
- Nayab, D.E.; Din, F.U.; Ali, H.; Kausar, W.A.; Urooj, S.; Zafar, M.; Khan, I.; Shabbir, K.; Khan, G.M. Nano biomaterials based strategies for enhanced brain targeting in the treatment of neurodegenerative diseases: An up-to-date perspective. J. Nanobiotechnol. 2023, 21, 477. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Pardridge, W.M. Treatment of Alzheimer’s disease and Blood-Brain barrier drug delivery. Pharmaceuticals 2020, 13, 394. [Google Scholar] [CrossRef] [PubMed]
- Sun, A.; Benet, L.Z. Late-Stage Failures of Monoclonal Antibody Drugs: A Retrospective Case Study Analysis. Pharmacology 2020, 105, 145–163. [Google Scholar] [CrossRef] [PubMed]
- ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/results?cond=alzheimers+and+parkinsons (accessed on 15 August 2021).
- Clene Awaits US Patent Covering Gold Nanocrystals’ Use in Treating MS. Available online: https://multiplesclerosisnewstoday.com/news-posts/2021/01/20/clene-awaits-us-patent-covering-gold-nanocrystal-use-ms-treatment/ (accessed on 15 August 2021).
- Eltanameli, B.; Sneed, K.; Pathak, Y. Nanomedicine and Nano Formulations for neurodegenerative Diseases. Biomedical. J. Sci. Tech. Res. 2022, 42, 33387–33396. [Google Scholar]
- Feng, L.; Wang, H.; Xue, X. Recent progress of nanomedicine in the treatment of central Nervous System Diseases. Adv. Ther. 2020, 3, 1900159. [Google Scholar] [CrossRef]
- Yarjanli, Z.; Kamran, G.; Abolghasem, E.; Soheila, R.; Ali, Z. Iron oxide nanoparticles may damage to the neural tissue throughiron accumulation, oxidative stress, and protein aggregation. BMC Neurosci. 2017, 18, 51–67. [Google Scholar] [CrossRef] [PubMed]
- Manickam, V.; Dhakshinamoorthy, V.; Perumal, E. Iron oxide nanoparticles induces cell cycle-Dependent neuronal apoptosis in mice. J. Mol. Neurosci. 2018, 64, 352–362. [Google Scholar] [CrossRef]
- Dhakshinamoorthy, V.; Manickam, V.; Perumal, E. Neurobehavioural toxicity of iron oxide nanoparticles in mice. Neurotox. Res. 2017, 32, 187–203. [Google Scholar] [CrossRef]
- Tereanu, D.M.; Chircov, C.; Grumezescu, A.M.; Volceanov, A.; Teleanu, R.I. Impact of Nanoparticles on Brain Health: An Up to Date Overview. J. Clin. Med. 2018, 7, 490. [Google Scholar] [CrossRef] [PubMed]
- Batool, S.; Sohail, S.; Din, F.U.; Alamri, A.H.; Alqahtani, A.S.; Alshahrani, M.A.; Alshehri, M.A.; Choi, H.G. A detailed insight of the Tumor targeting using nanocarrier drug delivery system. Drug Deliv. 2023, 30, 2183815. [Google Scholar] [CrossRef]
- Wei, M.; Yang, Z.; Li, S.; Le, W. Nanotherapeutic and Stem Cell Therapeutic Strategies in Neurodegenerative Diseases: A Promising Therapeutic Approach. Int. J. Nanomed. 2023, 18, 611–626. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Dri, D.A.; Rinaldi, F.; Carafa, M.; Marianecci, C. Nanomedicines and nanocarriers in clinical trials: Surfing through regulatory requirements and physico-chemical critical quality attributes. Drug Deliv. Transl. Res. 2023, 13, 757–769. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Halwani, A.A. Development of Pharmaceutical Nanomedicines: From the Bench to the Market. Pharmaceutics 2022, 14, 106. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Farjadian, F.; Ghasemi, A.; Gohari, O.; Roointan, A.; Karimi, M.; Hamblin, M.R. Nanopharmaceuticals and nanomedicines currently on the market: Challenges and opportunities. Nanomedicine 2019, 14, 93–126. [Google Scholar] [CrossRef]
- Choi, Y.H.; Han, H.-K. Nanomedicines: Current status and future perspectives in aspect of drug delivery and pharmacokinetics. J. Pharm. Investig. 2018, 48, 43–60. [Google Scholar] [CrossRef] [PubMed]
- Gadekar, V.; Borade, Y.; Kannaujia, S.; Rajpoot, K.; Anup, N.; Tambe, V.; Kalia, K.; Tekade, R.K. Nanomedicines accessible in the market for clinical interventions. J Control Release 2021, 330, 372–397. [Google Scholar] [CrossRef] [PubMed]
- Mühlebach, S. Regulatory challenges of nanomedicines and their follow-on versions: A generic or similar approach? Adv. Drug Deliv. Rev. 2018, 131, 122–131. [Google Scholar] [CrossRef] [PubMed]
- Gao, S.; Xu, B.; Sun, J.; Zhang, Z. Nanotechnological advances in cancer: Therapy a comprehensive review of carbon nanotube applications. Front. Bioeng. Biotechnol. 2024, 12, 1351787. [Google Scholar] [CrossRef]
- Hussaarts, L.; Mühlebach, S.; Shah, V.P.; McNeil, S.; Borchard, G.; Flühmann, B.; Weinstein, V.; Neervannan, S.; Griffiths, E.; Jiang, W.; et al. Equivalence of complex drug products: Advances in and challenges for current regulatory frameworks. Ann. N. Y. Acad. Sci. 2017, 1407, 39–49. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Krsek, A.; Baticic, L. Nanotechnology-Driven Therapeutic Innovations in Neurodegenerative Disorders: A Focus on Alzheimer’s and Parkinson’s Disease. Future Pharmacol. 2024, 4, 352-379. https://doi.org/10.3390/futurepharmacol4020020
Krsek A, Baticic L. Nanotechnology-Driven Therapeutic Innovations in Neurodegenerative Disorders: A Focus on Alzheimer’s and Parkinson’s Disease. Future Pharmacology. 2024; 4(2):352-379. https://doi.org/10.3390/futurepharmacol4020020
Chicago/Turabian StyleKrsek, Antea, and Lara Baticic. 2024. "Nanotechnology-Driven Therapeutic Innovations in Neurodegenerative Disorders: A Focus on Alzheimer’s and Parkinson’s Disease" Future Pharmacology 4, no. 2: 352-379. https://doi.org/10.3390/futurepharmacol4020020